Tuesday, 25 Jul 2017

You are here

Guselkumab for Active Psoriatic Arthritis

A double-blind, placebo-controlled, multicenter study aimed to evaluate efficacy and safety of a fully human monoclonal anti IL-23 antibody guselkumab (GUS), in patients with active psoriatic arthritis (PsA).  

Patients with active PsA and ≥3% body surface area of plaque psoriasis, both bio-naive and TNF experienced, were randomized 2:1 to receive GUS 100 mg subcutaneously (SC) or placebo (PBO) as follows:

 

  

Significant amount of patients in the treatment group achieved ACR 20 as early as week 4 (21% vs 0, p<0.001) and primary endpoint of ACR 20 response at wk24 was met in 58% of GUS patients RA as opposed to 18.4% in placebo group. Major secondary endpoints were PASI 75 and ACR 50 responses, change from baseline in HAQ-DI, and improvement in enthesitis (Leeds enthesitis index) and dactylitis score (by a 0–3 scoring system) at wk24 and were all significantly better in GUS group.

 

 

 

One patient in GUS groups developed grade 3 neutropenia that resolved after discontinuation of treatment. Infections were the most common AEs (PBO: 20.4%; GUS: 17.0%, respectively).

 

Overall, study concluded GUS demonstrated significant improvement of arthritis, psoriasis, enthesitis, dactylitis and quality of life and was well tolerated with no unexpected safety signals.

Add new comment

More Like This

The RheumNow Week in Review – 21 July 2017

Dr. Jack Cush reviews the news from the past week on RheumNow.com: 

The RheumNow Week in Review – 14 July 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

Pharma Pays $8.2 Billion to Physicians in 2016

Data made public by the Centers for Medicare & Medicaid Services shows that drug and device makers made nearly $8.2 billion in payments to U.S. physicians and teaching hospitals in the last year. Since 2013, CMS has been tracking physician payments as part of the Affordable Care Act.

The RheumNow Week in Review – 30 June 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

ACR Says Senate Healthcare Bill Falls Short of Protecting Americans with Rheumatic Disease

Dr. Sharad Lakhanpal, President of the American College of Rheumatology has responded to the Senate's proposed changes to healthcare coverage in the USA.